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Abstract: Lung cancer (LC) and colorectal cancer (CRC) are the second- and third-most 
commonly diagnosed cancers in the Veterans Affairs (VA) health care system. While many stud-
ies have evaluated the treatment quality and outcomes of various aspects of VA LC and CRC 
care, there are no known reviews synthesizing this information across studies. The purpose of 
this literature review was to describe LC and CRC treatment (ie, surgical and nonsurgical) and 
outcomes (eg, mortality, psychosocial, and other) in the VA health care system as reported in the 
existing peer-reviewed scientific literature. We identified potential articles through a search of 
published literature using the PubMed electronic database. Our search strategy identified articles 
containing Medical Subject Headings terms and keywords addressing veterans or veterans’ health 
and LC and/or CRC. We limited articles to those published in the previous 11 years (January 
1, 2003 through December 31, 2013). A total of 230 articles were retrieved through the search. 
After applying the selection criteria, we included 74 studies (34 LC, 47 CRC, and seven both 
LC and CRC). VA provides a full array of treatments, often with better outcomes than other 
health care systems. More work is needed to assess patient-reported outcomes.
Keywords: colorectal neoplasms, health services research, lung neoplasms, outcome assess-
ment (health care), review, United States Department of Veterans Affairs
Introduction
Lung cancer (LC) and colorectal cancer (CRC) are the second- and third-most com-
monly diagnosed cancers among men and women in the US, together accounting for 
approximately 20% of all new cancer cases annually.1 In 2014, an estimated 224,210 LC 
and 136,830 CRC cases along with 159,260 LC and 50,310 CRC deaths will occur.1 
Age and cigarette smoking are the predominant risk factors for LC, although other 
environmental and occupational exposures, such as asbestos and radon, may also 
increase lung cancer risk.2 Well-known risk factors for CRC include age, obesity, 
physical inactivity, alcohol consumption, and unfavorable dietary habits, such as 
increased red and processed meat consumption and low fruit and vegetable intake.3,4 
Cancer care is complex, and a number of organizations have set forth guidelines for 
the management of LC and CRC care.
Patients with cancer receiving care in the Veterans Affairs (VA) health care system 
represent about 3% of all cancer patients in the US.5 A national-level study using the 
VA Central Cancer Registry to assess cancer incidence among veterans noted that 
lung and bronchus cancers account for nearly 20% of all cancers among veterans, and 
CRC accounts for 9%.5 While comparisons have been made between VA and non-VA 
care for both LC and CRC,6–10 the VA population is unique in that most patients have 





poor health and lower education and income.11–14 Given the 
aging population, increase in military personnel exiting active 
duty, and potential increase in veterans seeking health care in 
VA, the cancer burden in VA will increase. Therefore, it is 
important to assess current treatment practices and impact 
on outcomes in the VA cancer population to identify areas 
for improvement.
The objective of this review was to describe LC and 
CRC treatment (ie, surgical and nonsurgical) and outcomes 
(eg, mortality, psychosocial, and other) in the VA health care 
system as reported in the existing peer-reviewed scientific 
literature. To our knowledge, this is the first comprehensive 
review of cancer treatment and outcomes in patients receiv-
ing care in the VA health care system.
Materials and methods
We identified potential articles through a search of pub-
lished literature using the PubMed electronic database. Our 
search strategy identified articles containing Medical Subject 
Headings and keywords in the title and abstract addressing 
veterans or veterans’ health and LC and/or CRC (Table 1). We 
limited articles to those published in English in the previous 
11 years (January 1, 2003 through December 31, 2013).
This initial search yielded 230 unique articles. We then 
screened abstracts and full articles for eligibility. The fol-
lowing exclusion criteria were applied: non-US veterans 
(or inability to distinguish between veterans and nonveter-
ans in the study population), noncancer or other cancers, 
nonepidemiological or not original research (eg, commentar-
ies, feasibility studies), or description of only risk or barriers 
to care. We included retrospective analyses, cross-sectional, 
and prospective studies. A full description of this process is 
outlined in Figure 1.
Results
A summary of published studies describing LC and 




There were eight articles that addressed receipt of surgery 
and/or predictors of surgical treatment. Dransfield et al 
reported that among 156 patients with non-small-cell LC 
(NSCLC), 31 underwent resection, and a majority of these 
(61%) were diagnosed at the time of surgery.15 In a study 
including all patients diagnosed with LC in 2007, the surgery 
rate was 69% (909 of 1,314) among those with stages I and II 
NSCLC.16 This was similar to the 65.4% of stage I and II 
NSCLC patients who received surgery in the full cohort in 
the VA-wide study by Landrum et al of patients diagnosed in 
2003–2004.17 In another national-level cohort of VA patients, 
51% of patients aged 65 years and older with localized LC 
had surgery.18 Zeber et al conducted a national-level study 
of elderly veterans comparing receipt of treatment for LC 
patients aged 70–84 years (n=19,010) to those 85 years 
and older (n=1,347), and found that 2.7% of all LC patients 
aged 70–84 years had surgery compared to 0.5% of those 
over 85 years.19 When surgical resection patterns among 
veterans and nonveterans were compared, it was noted that 
resection rates were similar for older veterans (70.2%) and 
nonveterans (71.2%) with early stage disease, but among 
younger patients the resection rate was lower in veterans 
(83.3%) compared to nonveterans (91.5%).20 In two small 
studies, each done at a single VA facility, one study observed 
that 20% of stage I–IIIA patients got surgery,15 and the other 
reported a 28% surgery rate among all stages.21
Four of these seven studies identified factors associated 
with receipt of surgery. In a single-institution study, the 
authors noted that surgery patients were less likely to have 
chronic obstructive pulmonary disease (COPD) and typically 
had better pulmonary function, while those who did not 
have surgery most often had advanced disease (75%), poor 
pulmonary function (5%), or refused (4%).15 National-level 
studies by Williams et al and Wang et al both reported that 
lower treatment rates were associated with increasing age, 
Table 1 Search strategy for veterans Affairs (vA) lung and 
colorectal cancer treatment and outcomes
Database PubMed




((((“United States Department of veterans Affairs” 
[MeSH] OR “hospitals, veterans” [MeSH] OR “veterans 
health” [MeSH] OR “veterans” [MeSH]) AND (“lung 
neoplasms” [MeSH] OR “colorectal neoplasms” [MeSH]) 
AND (“2003/01/01” [PDAT]: “2013/12/31” [PDAT]))) 
OR ((((lung cancer [title/abstract]) OR colorectal cancer 
[title/abstract]) OR colon cancer [title/abstract]) OR 
rectal cancer [title/abstract])) AND ((veteran [title/
abstract]) OR vA [title/abstract])
exclusion 
criteria
•  Non-english language
•  Non-US veterans (or inability to distinguish between 
treatment/outcomes of veterans and nonveterans 
within the article)
•  Noncancer or other cancers
•  Nonepidemiological or not original research (eg, 
commentaries, feasibility studies)
•  Described only risk or barriers to care
Abbreviations: MeSH, Medical Subject Headings; PDAT, publication date.
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black race, severe comorbidity, and respiratory  disease.16,18 
For example, resection rates for local disease among 
patients 65–74 years old were 59.8% and 43.1% for those 
aged 75–84 years and 18.5% for those over age 85 years.18 
Williams et al reported that blacks were significantly less 
likely to receive surgery compared to whites (odds ratio 
0.63, 95% confidence interval [CI] 0.48–0.83), and receipt 
of surgery also varied within the categories of marital sta-
tus, histology, smoking status, and region.16 In an article 
by Landrum et al that identified reasons for not receiving 
guideline-recommended treatment,  predominant reasons for 
nonreceipt of curative surgery for stage I/II LC included poor 
health (61%) and refusal (26%).17
Nonsurgical treatment
We identified two studies that evaluated receipt of nonsurgical 
treatment, both of which were done among elderly veterans. In 
an article by Wang et al, the authors used a cohort of patients 
aged 65 years and older to assess receipt of first-line recom-
mended treatment according to National Comprehensive 
Cancer Network guidelines.18 The recommended treatment 
for regional NSCLC is surgery plus chemotherapy, with 
or without radiation if the patient is eligible for surgery, or 
chemotherapy plus radiation if the patient is not a surgical 
candidate. Chemotherapy is the standard of care for patients 
with metastatic disease. Based on these guidelines, this study 
found that 35% of patients with regional disease and 27% with 
metastatic disease received appropriate treatment. Treatment 
rates varied a great deal according to age. For patients with 
regional disease, rates ranged from 44.7% for those aged 
65–74 years to 14.0% for those over 85 years. Corresponding 
rates for metastatic disease were 34.3% and 9.3%. Zeber et al 
examined treatment modalities using a cross-sectional study 
of patients aged 70 years and older.19 Among LC patients 
aged 70–84 years, 4.8% received radiation and 9.0% received 
chemotherapy. For patients aged 85 years and older, 3.3% got 
radiation, while 2.9% got chemotherapy.
Timeliness of care
When the timeliness of LC care is considered, it is impor-
tant to note that although several studies have evaluated 
“guideline-recommended” timeliness, these guidelines are 
not based on scientific evidence that shorter time periods 
produce better outcomes. In the period for the literature 
search for this review, there were seven studies published on 
the timeliness of LC care among veterans. Three national-
level studies examined the timeliness of care within VA. 
One of these studies found that the median time between 
the first radiography and treatment was 71 days,22 while 
another study reported the median times between suspicion 
and diagnosis as 33 days and suspicion to treatment as 63 
days.23 A national-level study among late-stage NSCLC 
Articles identified via PubMed search 
and eligible for abstract screening
(n=230) 








Barriers to care (n=2)
Nonepidemiological (n=44)
Risk (n=7) 
Lung cancer (n=34, seven
of which included
colorectal cancer) 
Full-text articles included in review
(n=74) 
Colorectal cancer (n=47,
seven of which included
lung cancer) 






Figure 1 Schema for article-selection process.




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































patients reported 66 days as the mean time from diagnosis 
to  initiation of treatment.24 The studies including all LC 
stages; both reported shorter time to treatment for advanced 
stages,22,23 one of which found that patients receiving radia-
tion or chemotherapy were treated sooner than those under-
going surgery.22 Another noted a 69% adherence rate to the 
recommended guideline for receipt of diagnosis within 8 
weeks of suspicion.23 
Wang et al compared time to treatment in a single VA 
compared to a nearby academic medical center, and found 
that the median time to treatment was longer for patients 
treated in VA (67 days) than for patients treated at a hospital 
(55 days).25 The other studies examining the timeliness of 
care were each conducted at a single VA facility. One facility 
evaluated the impact of having a cancer care coordinator to 
improve timeliness of care for patients potentially having LC,26 
and found that the time between suspicion and treatment was 
reduced to 55 days, compared to 136 days in previous years. 
On the contrary, incorporation of a multidisciplinary thoracic 
oncology clinic at another facility did not appear to improve 
times to diagnosis and treatment.27 The time intervals between 
initial presentation to diagnosis before and after initiation of 
the multidisciplinary thoracic oncology clinic were 47 days 
and 48 days, respectively.27 Corresponding times between 
diagnosis and treatment were 22 and 23 days, respectively.27 
Another single-facility study documented 84 days between 
suspicion and treatment (range 38–153 days).21 This study 
further determined that predictors of timely treatment included 
hospitalization within 7 days of the initial cancer suspicion, a 
tumor size greater than 3.0 cm, other abnormalities on chest 
radiograph, and presence of metastatic symptoms, and deter-
minants of timely diagnosis included hospitalization within 7 
days, tumor size greater than 3.0 cm, and white race.
Postoperative outcomes
In a retrospective review of 78 patients undergoing surgery 
for pathologic stage I LC, approximately a third of patients 
had at least one postoperative event, with the most common 
being pneumonia (17%) and reintubation (13%).28 Another 
small study comparing video-assisted thoracoscopic (VATS) 
lobectomy (n=46) with open lobectomy (n=45) found that 
VATS patients had a shorter length of stay and shorter chest-
tube duration and that VATS was associated with a lower risk 
of complications.29 DeArmond et al also examined patients 
undergoing VATS lobectomy, and compared outcomes of 
VA and non-VA patients.30 They noted that average length of 
stay was significantly longer in VA versus non-VA patients 
(6.4 days versus 3.6 days, P=0.022).











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In a study by Dransfield et al, overall survival rate at 3 years 
was 65% among surgical patients, 80% among stage IA sur-
gical patients in particular, and 30% in nonsurgical patients.15 
Another single-facility study of 178 resection patients 
reported that 102 (57%) patients died during the study 
period, of whom 60% died from disease-specific causes, 18% 
from other causes, and 25% from unknown causes.31 As it 
relates to short-term outcomes, one study found 30-day and 
90-day mortality rates to be 3.8% and 6.4%, respectively, 
among pathologic stage IA resection patients.28 
In studies evaluating predictors of survival, factors asso-
ciated with worse survival included an increasing number 
of postoperative events28 and shorter times to treatment.21 
While the correlation between shorter time to treatment and 
worse survival outcomes may be due to a myriad of factors, 
it is possible that this can also be attributed to patients with 
more advanced disease. One VA-wide study of patients with 
late-stage NSCLC found that African-Americans had longer 
overall survival (133 days) than whites (117).24 Three of the 
eight studies evaluating survival in veterans with LC were 
done at the state or national level, and compared survival 
among VA versus non-VA patients. Campling et al identified 
new LC patients diagnosed in 1995–1999 from the Pennsyl-
vania Cancer Registry (n=28,798) to compare patient char-
acteristics and survival among VA and civilian patients.32 VA 
patients had worse overall survival, based on 5-year survival 
rate of 12% among VA patients and 15% among non-VA 
patients. When examined by race, this significant survival 
difference among VA and non-VA patients was observed in 
white patients but not blacks. A similar comparative analysis 
was conducted among patients in Washington state diagnosed 
with LC between 2000 and 2006 identified by the VA and 
Surveillance, Epidemiology, and End Results (SEER) cancer 
registries.20 Veterans had worse survival within each stage 
compared to non-VA patients, but better overall survival 
when stages were combined, because VA had a significantly 
greater percentage of early-stage diagnoses. 
Only one national-level study was done, and showed that 
VA patients had improved overall and cause-specific survival 
rates for NSCLC compared to SEER Medicare patients 
(hazard ratio [HR] 0.91, 95% CI 0.88–0.95), primarily due 
to more early stage patients in the VA population, because 
this survival benefit was no longer evident in stage-adjusted 
analyses.8 There was no survival difference for small-cell 
lung cancer (SCLC) (HR 0.99, 95% CI 0.93–1.05). Also, 
survival outcomes were similar for VA and non-VA patients 
undergoing similar LC treatment.
Other outcomes
Two studies assessed health care utilization among LC 
patients. Au et al examined health care utilization in the 
last 6 months of life in patients with LC versus COPD who 
received care in one of seven VA facilities.33 Compared to 
those with COPD, LC patients were less likely to see their 
primary care provider and admitted to the intensive care 
unit less often, but more LC patients received palliative 
medications. A VA facility in the Midwest evaluated use 
of primary care before and after LC diagnosis, and reported 
no significant change in the overall primary care-utilization 
rate for chronic conditions (eg, hypertension), but found a 
significant decrease for acute conditions (eg, lower respira-
tory infection).34 A small study among advanced LC patients 
found that 53.2% discontinued statin use prior to death, and 
this was most often those receiving chemotherapy or with a 
history of cerebrovascular disease.35
We identified one study each that assessed communica-
tion, cost, and symptom management in two postdiagnostic 
clinic contexts: postangiogram consultations and initial 
lung cancer visits.36 Postdiagnostic patient–provider com-
munication was compared between 88 patients during their 
postangiogram consultation and 62 patients during their 
initial LC visit.36 This study noted a greater frequency of 
active participation for LC patients and more facilitative 
talk by physicians of LC patients. Keating et al conducted a 
retrospective study to evaluate variation in area-level Medi-
care spending for cancer care.6 They did not find NSCLC to 
be associated with area-level spending in VA; however, the 
results suggested that the effects of spending on mortality 
in VA may be different than in the private sector. One study 
evaluated treatment with erythropoiesis-stimulating agents 
(ESAs) for anemia among 17,014 LC patients.37 In 2007, the 
US Food and Drug Administration issued a black-box warn-
ing for ESAs, because under certain circumstances ESAs may 
increase the risk of death and cancer progression. The study 
found that patients receiving chemotherapy after March 2007 
had 65%-reduced odds of ESA treatment compared to those 
treated with chemotherapy before 2007.37
Colorectal cancer
Surgical and presurgical treatment
We identified four studies evaluating preparation for and/or 
receipt of surgery. Mauchley et al examined the clinical utility 
of routine preoperative computed tomography (CT) scans and 
their cost-effectiveness in the treatment of patients with colon 
cancer; CT scans provided information that was used in treat-
ment planning (33% of patients), and sometimes altered the 
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model of treatment (16% of patients).38 Routine preoperative 
CT scans were also cost-effective, saving the institution in 
excess of US$24,000 over a 6-year period.38 A national-level 
study of VA medical centers (VAMCs) using National Surgi-
cal Quality Improvement Program (NSQIP) data examined 
causes of mortality in CRC surgery and the longitudinal 
uptake of both cancer- and noncancer-directed laparos-
copy.39 Over a 3-year period, the percentage of laparoscopy, 
a minimally invasive surgery, gradually increased from 3.5% 
(2003) to 10.1% (2005). Balentine et al used a database at 
their facility to evaluate minimally invasive CRC surgery 
among obese patients over an 8-year span (2002–2009).40 Of 
these obese patients, 73% (n=113) underwent open surgery, 
and 27% (n=42) had minimally invasive surgery. Conversion 
from open to minimally invasive surgery occurred in 25% 
of cases. At the Houston VAMC, Abraham et al examined 
receipt of appropriate therapy according to the National 
Cancer Institute’s Physician Data Query (ie, stage II colon 
cancer patients receive surgical resection, stage III both 
surgery and chemotherapy).41 They found that most (87% of 
stage II and 71% of stage III) colon cancer patients received 
the recommended therapy, while fewer than half (42.5%) of 
rectal cancer patients did. Among patients with rectal cancer, 
those whose clinical case was discussed at tumor board were 
more likely to receive the recommended therapy.41
Hynes et al addressed issues of cancer-care coordina-
tion among dually eligible patients (ie, eligible for VA 
and Medicare coverage).42 Among veterans with CRC in 
California, 72% were initially diagnosed and treated in non-
VA facilities.42 The authors compared surgery and adjuvant 
chemotherapy use between older California-based veterans 
with cancer receiving care in the VA system, outside of the 
VA system, and in both VA and non-VA systems. The odds 
of receiving cancer-directed surgery and chemotherapy were 
similar in both systems. Also, in both care settings, among 
stage III patients older age was associated with lower odds 
of receiving adjuvant chemotherapy.42 Zeber et al conducted 
a national-level study of elderly veterans comparing receipt 
of treatment for CRC patients aged 70–84 years (n=23,494) 
to those 85 years and older (n=2,806), and found that 5.8% of 
patients aged 70–84 years had surgery compared to 3.4% of 
those over 85 years.19 When Landrum et al examined reasons 
for underuse of recommended treatment, African-American 
veterans were less likely to receive rectal surgery (66.6% 
versus 80.7%, P=0.002), and curative surgery refusal rates 
were higher for African-Americans with stages I–III rectal 
cancer compared to white patients (14.6% versus 4.8%, 
P=0.001).17
Nonsurgical treatment
Keating et al compared area-level variations in Medicare 
spending, cancer care received, and outcomes between 
patients enrolled in fee-for-service Medicare and VA.6 In 
contrast to the fee-for-service Medicare cohort, in the VA 
system there was minimal variation in CRC treatment by 
spending.6 In a study by Landrum et al evaluating dual users, 
relative to users of one system (ie, either VA or non-VA), 
dual users with stage II and III were substantially less likely 
to receive chemotherapy.8
We identified two studies evaluating possible racial 
variation in the provision of nonsurgical VA CRC care and 
one study evaluating variation by age. In a single-facility 
study, Sabounchi et al found that use of chemotherapy was 
significantly higher in white than black veterans (49% versus 
25%, P,0.001); however, there was no difference in receipt 
of radiotherapy.43 In a national-level study, Zullig et al found 
no racial difference for receipt of guideline-concordant CRC 
care, including preoperative carcinoembryonic antigen test-
ing and surveillance colonoscopy.44 However, the authors 
determined that VA patients who were older at diagnosis may 
have had reduced odds of referral to medical oncology and 
surveillance colonoscopy.44 Zeber et al examined treatment 
modalities using a cross-sectional study of patients aged 
70 years and older.19 Among CRC patients aged 70–84 years, 
1.3% received radiation and 3.9% received chemotherapy. 
For patients 85 years and older, 1.0% got radiation, while 
1.2% got chemotherapy.
Timeliness of care
We identified five studies addressing timeliness of VA CRC 
care. Paulson et al found that compared to colon cancer patients 
treated entirely within their home VAMC, patients who required 
referral to a different hospital (ie, outside of their home VAMC) 
for surgery experienced delays in surgical intervention.45 For 
patients referred outside VA, there was an average delay of 
nearly 2 weeks. Those who then returned to VA for chemo-
therapy were more likely to receive initial treatment more than 
8 weeks after surgery. Patients who went to another hospital to 
receive chemotherapy experienced delays; the average adjusted 
time from surgery to chemotherapy for these patients compared 
to those treated entirely within the VA health care system was 
11.4 days (P=0.003).45 Similarly, Merkow et al examined time 
from CRC diagnosis to first-course therapy, and found that time 
to first treatment increased over the study period (1998–2008) 
for both colon and rectal cancers.46
We identified one national47 and one single-facility 
study48 examining racial differences in CRC-care timeliness. 





Zullig et al evaluated racial differences in stage-specific timeli-
ness measures, such as time from surgery to initiation of adju-
vant chemotherapy and surgery to surveillance colonoscopy. 
Though there was a small (average 16 days) racial difference 
in time to surveillance colonoscopy, the authors concluded 
that there was little evidence of racial differences in CRC 
quality among VA health care-system users.47 The single-study 
facility observed no significant racial difference in mean times 
from diagnosis to surgery.48 Another VA-wide study observed 
a delay to perform surgeries, both cancer- and noncancer-
directed surgeries, in 23 patients (22%).39
Postoperative outcomes
A single-institution study reported that robotic rectal resec-
tion compared to laparoscopy was associated with longer 
operative times, but there was no difference in surgical 
outcomes, such as blood loss, conversion rates, postopera-
tive morbidity, lymph nodes harvested, margin positivity, or 
specimen quality.49 A national-level study examined patient 
characteristics, with special emphasis on race, associated 
with clear surgical margins for nonmetastatic CRC resec-
tion, and determined that there were no racial differences 
in clear surgical margins.44 In a study by Lee et al among 
surgical patients, compared to patients under 80 years old 
who had also had CRC-directed surgery, those 80 years and 
older had an increased length of stay (21.4±4.1 days for 
study group versus 11.1±0.9 days for control group, P=0.02) 
and more cardiopulmonary complications (P=0.01), and 
32% presented in an emergency situation, which resulted in 
significantly longer hospital stays and increased incidence 
of complications.50
We identified two studies, one local and one national, 
addressing lymph-node retrieval. At a national level, 
Gonsalves et al evaluated clinical, pathological, and patient 
factors associated with lymph-node retrieval.51 The authors 
identified patients with resected stage I–III colon cancer 
between 2005 and 2008. They found that the mean number 
of lymph nodes retrieved increased over time, and was asso-
ciated with higher stage, higher tumor descriptor, age less 
than 65 years, poorer differentiation, and right-side tumors 
(P,0.01 for all of these factors).51 Another study at the 
VAMC in Houston, TX reported an increased percentage of 
complete, margin-negative resections (P,0.05) and number 
of lymph nodes removed during surgery (P,0.01) after estab-
lishing a minimally invasive CRC program.52 Investigators 
also compared outcomes of patients undergoing minimally 
invasive laparoscopic resections to age-matched patients who 
underwent open resections.53 They determined that patients 
undergoing laparoscopic procedures experienced shorter 
hospital stays and quicker return of bowel function.53 In 2009, 
the median inpatient cost of laparoscopic colectomy was 33% 
less than open colectomy ($6,000, P,0.01).54 The median 
length of stay in the hospital and operative time were also 
reduced by 31% (3.5 days, P,0.05) and 37% (108 minutes, 
P,0.01), respectively, among those undergoing laparos-
copy.54 Compared to those undergoing open CRC surgery, 
obese patients undergoing minimally invasive surgery had 
a significantly faster return of bowel function and returned 
home a median of 2 days earlier (P,0.01).40 In a retrospec-
tive analysis of patients undergoing resection from 2002 to 
2007, the median length of stay was 8 days.55 In this study, 
coronary artery disease and postoperative complications were 
predictive of prolonged length of stay; COPD was predictive 
of complications.55
Survival outcomes
We identified two studies that assessed temporal trends in 
CRC mortality. The first VA-wide analysis evaluated tem-
poral trends in survival among CRC patients admitted to 
VA hospitals.56 Significant survival differences were seen 
over time (1987–1998, P,0.01) with longer survival times 
for patients diagnosed in more recent periods of time. In an 
adjusted analysis, there was an 18% increase in survival over 
time, and a small but significant decrease in the chance of 
surviving, in blacks compared to whites (adjusted relative sur-
vival 0.96, 95% CI 0.92–0.99).56 The second study examined 
temporal changes in 30-day postoperative mortality using 
NSQIP data.57 Thirty-day postoperative mortality declined 
from 4.7% during 1987–1988 to 3.9% during 1998–2000. 
Patients who received surgical resection during 1992–1994, 
1995–1997, and 1998–2000 had a 14%, 14%, and 27% lower 
adjusted risk of 30-day mortality, respectively, compared 
with those resected in 1987–1988.57 In another study of all 
VAMCs, the 30-day postsurgery mortality rate was 5.9%. 
Visser et al measured both 30- and 90-day mortality follow-
ing colectomy at a single facility.58 In this study, laparoscopic 
operations comprised 24.2% and open operations comprised 
75.8% of colorectal surgery; most (60.8%) were surgeries 
performed for neoplasms.58 The actual 30-day mortality rates 
were 4.3%, 1.4%, and 15.8% for all, elective, and emergency 
procedures, respectively.58 They compared these rates to 
calculated NSQIP rates. The observed and calculated rates 
were similar. The risk-adjusted observed-to-expected ratio for 
30-day mortality was 4.8%, 1.8%, and 18.2%, respectively. 
However, 90-day mortality increased substantially to 9.1%, 
4.1%, and 28.9%, respectively.58
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Numerous studies examined patient, hospital, or provider 
factors associated with survival. van Roessel et al determined 
that compared to National Cancer Database benchmarks, 
their VA facility had a greater percentage of early-stage 
cancers and better all-cause 5-year survival (VA 0.72, 
National Cancer Database 0.47; P,0.001).59 We identified 
five studies addressing the correlation between patient factors 
and survival risk for VA patients with CRC. Rabeneck and 
colleagues compared 30-day and 5-year mortality in elderly 
versus younger patients following CRC-directed surgical 
resection. In patients at least 65 years of age with rectal 
or colon cancer, after adjustment the 30-day mortality was 
2.5 times greater and 5-year mortality was 1.5 times greater 
than in younger patients.60 Lee et al also assessed the impact 
of age on survival by evaluating outcomes of patients aged 
80 years and older who underwent surgery for CRC between 
1996 and 2006. Older patients also had decreased survival 
rates at 1, 3, and 5 years (71%, 48%, and 31% respectively).50 
After stratifying by stage, survival between diabetic and non-
diabetic patients with CRC was not significantly different.61 
Two single-facility studies43,48 and one national study47 noted 
no racial differences in survival.
Landrum et al compared the survival rates of older patients 
with cancer receiving care in the VA health care system and 
fee-for-service Medicare.8 When compared to similar fee-for-
service Medicare patients, patients receiving VA care had higher 
survival rates for colon cancer (HR 0.87, 95% CI 0.82–0.93) 
and similar survival rates for rectal cancer (HR 1.05, 95% CI 
0.95–1.16).8 One study compared 3-year overall and cancer-
free survival among patients with nonmetastatic colon cancer 
between patients who received substantial proportions of their 
care in both VA- and non-VA systems (dual users) and those 
who obtained care predominantly in VA or a non-VA system.9 
Patients with stage I disease who received care predominantly 
in either VA (HR 0.40, 95% CI 0.28–0.56) or a non-VA system 
(HR 0.54, 95% CI: 0.38, 0.78) had reduced hazard of dying 
compared with dual users. This was true for all stages of disease. 
For event-free survival, stage II and III VA users, but not non-
VA users, had improved event-free survival.9 Dual users also 
had fewer total provider visits for colon  cancer. In a study by 
Keating on area-level variation, in VA there was no statistically 
significant association of care delivered or mortality based on 
the level of Medicare spending.6
Greater surgical volume at a facility is a predictor of sur-
vival following CRC surgery.62 Among newly diagnosed CRC 
patients who underwent surgical resection in the VA system 
in fiscal years 1991–2000, 5-year cumulative survival was 
52.1% among patients who received surgery in high-volume 
surgical hospitals, ie, those performing $25 procedures 
annually, compared to 48.1% in low-volume hospitals.62 
In adjusted analyses, there was a 7% and 11% increase in 
5-year survival for patients with colon and rectal cancers, 
respectively, compared to patients undergoing surgical resec-
tion in high- versus low-volume hospitals.62 Among stage II 
patients, overall survival increased with the higher number of 
lymph nodes examined and overall survival was greater with 
an increased number of positive lymph nodes (P,0.001).63 
The ratio of examined-to-positive lymph nodes was a stronger 
predictor of survival, with a 5-year overall survival of 27% for 
the highest quartile versus 44% for the lowest.63
Fisher et al64 compared the mortality rates of patients 
who received at least one colonoscopy after their diagnosis 
with patients who had no further procedures. The adjusted 
risk of death at any point during 5 years of follow-up was 
decreased by 43% (HR 0.57, 95% CI 0.51–0.63) in the group 
who had a surveillance colonoscopy versus those who did 
not.64 The absolute difference in 5-year mortality rate was 
approximately 12%.64
Other outcomes
We identified few studies (n=3) addressing symptom manage-
ment and psychosocial outcomes. In a national retrospective 
analysis examining ESA use for anemia management among 
colon cancer patients receiving chemotherapy, the odds of 
receiving ESA treatment decreased by 53% (OR 0.47, 95% 
CI 0.36–0.63) after the US Food and Drug Administra-
tion warning in 2007 compared to those treated before the 
warning.37
Two articles focused on psychosocial aspects of health 
and/or palliative care. The majority (78.6%) of VA CRC 
patients obtain psychosocial services.65 The most commonly 
accessed type of psychosocial service was chaplain services 
(58.9%), followed by social work (50.5%), psychiatry 
(7.1%), psychology (6.2%), mental health nurses (3.5%), or 
another type of service (4.4%).65 Phelan et al reported results 
from a self-administered survey to assess stigma, perceived 
blame, self-blame, and depressive symptoms in men with 
CRC, and indicated that 31% of survey respondents agreed 
with at least one item in a measure of cancer stigma, and 25% 
reported feeling at least a little to blame for their illness.66 
Feelings of cancer stigma and self-blame were independent 
predictors of depressive symptoms.66
Lung and colorectal cancer
In a study including patients with metastatic LC or CRC, 
but not distinguishing between the two, Keating et al found 





that compared with fee-for-service Medicare, patients with 
metastatic cancer in the VA health care system appropriately 
received less aggressive end-of-life care.7 In particular, 
among matched cohorts, men in VA were less likely to 
receive chemotherapy within 14 days of death, be admitted 
to the intensive care unit within 30 days of death, or have 
more than one emergency room visit within 30 days of their 
death.7 This suggests that patients in VA may be receiving 
appropriate palliative care.
Discussion
The VA health care system is the largest integrated system 
in the US, and one of the largest providers of cancer care.5 
Moreover, VA fulfills an important role by serving a unique 
patient population. VA patients often enter the health care sys-
tem with a greater comorbidity burden, lower education and 
income, and lower health literacy.11–14 This literature review 
described treatment-utilization rates, factors associated with 
receipt of treatment, and outcomes for LC and CRC within 
the VA health care system.
Summary of vA LC care
Evidence from the reviewed studies on LC shows that resec-
tion rates were 65%–70%, and closer to 50% among elderly 
populations. Among demographic factors, besides age, black 
race was also associated with lower resection rates, which has 
been widely reported for decades.67 Clinical predictors of non-
receipt of surgery included such conditions as COPD and poor 
pulmonary function, as expected, since these are related to 
lung disease, and severe comorbidity. Together, these findings 
stress the need to identify ways to reduce variation in treat-
ment by population subgroups, understand determinants of 
patient decisions regarding treatment, and identify any unmet 
patient needs or concerns that could improve resection rates. 
A significant portion of patients did not get recommended 
treatment for advanced disease; however, studies were few 
and confined to elderly populations. Studies assessing timeli-
ness of care generally noted shorter times to care for advanced 
stages. Although some delay in lung cancer treatment is 
inevitable, due to the complexity of disease, large studies 
should attempt to identify and reduce any avoidable delay and 
assess the impact of delay on long-term outcomes. Numerous 
studies addressed survival outcomes among LC patients, but 
very few examined other patient outcomes (eg, quality of life, 
follow-up care, recurrence), and most studies were small. This 
is certainly an area for much-needed research to understand 
the impact of lung cancer care on both patient-reported and 
other clinical outcomes.
Summary of vA CRC care
Earlier stage at presentation was not associated with race, but 
was associated with improved long-term survival. In general, 
CRC patients receiving care in VA received appropriate cancer 
treatment44,68,69 and palliative care.7 Outcomes for older patients 
may be worse than younger patients and/or those with fewer 
comorbid conditions; while older patients may be less likely 
to receive certain types of treatment, such as chemotherapy, 
care is provided to older VA CRC patients at a similar rate 
as in the private sector. Overall, racial variation in VA CRC 
care is not evident, although there is room for improvement 
in a few areas, such as racially equal uptake of chemotherapy. 
The survival rates of older men with rectal and colon cancer 
are equal to and better than, respectively, the survival rates of 
men receiving care in fee-for-service Medicare.
Summary of vA and non-vA comparisons
Studies comparing VA and non-VA health care settings found 
mixed results with respect to quality of care and survival 
between patients treated within and outside VA. In terms 
of cancer-care quality, several studies indicated that qual-
ity indicators, such as length of stay after LC surgery30 and 
time to LC treatment,25 were better in settings outside VA. In 
contrast, other studies also reported improved quality within 
VA compared to non-VA settings. For example, studies found 
that VA LC patients were diagnosed at earlier stages,8,20 and 
both LC and CRC patients received less aggressive end-of-
life care.7 Additionally, compared to CRC patients seeking 
care in the private sector, those with higher comorbidity 
burden were diagnosed at an early stage.10 There were also 
conflicting findings in terms of survival benefit between 
patients treated in VA and non-VA systems. For example, one 
study32 found that VA LC patients had worse overall survival 
than non-VA patients; however, two other studies found that 
VA LC patients had better all-cause8,20 and cancer-specific 
survival.8 Better overall survival was also found among VA 
CRC patients.59 Findings were consistent regarding the perils 
of receiving care in dual systems: receiving care in one sys-
tem, whether VA or non-VA, leads to better wait times and 
survival compared to using multiple systems.9,45
Limitations
This review has several limitations. First, we synthesized the 
literature describing treatment and outcomes of care provided 
in the VA health care system. Care provided to veterans 
outside VA, either in nonfederal systems or through dual 
use of multiple systems, was not captured in this review. 
The extent of veterans receiving cancer care outside VA is 
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not known. Secondly, these studies were dissimilar in many 
ways; lack of congruence in study design and content makes 
comparisons between VA and non-VA settings, as well 
as across VA settings, challenging. The included studies 
varied widely in terms of study population (eg, one center 
versus nationwide), study time frames, comparison groups 
(eg, another integrated health care system versus national 
database), and sample size. Because of heterogeneity in 
research design, there are limitations in the extent to which 
conclusions can be synthesized across studies.
Future directions
Mirroring that of those in military service, the composition of 
the VA population is changing. The VA serves an increasingly 
younger population with more female patients.70 As a result 
of this population shift, cancer-related treatment needs may 
also evolve. The VA cancer population approximately paral-
lels that of US men;5 however, as more women receive care 
in VA, it is possible that VA may see an increase in cancers 
that are common among women. More research is needed 
to understand how and/or if VA should modify its cancer 
planning and services.
Relatively few studies included patient-reported outcomes 
and care experiences. Patient-reported information could lend 
additional insight into experiences of symptoms, functioning, 
health status, and quality of life. Understanding the patient 
perspective may provide critical insight into psychosocial 
needs, an underevaluated aspect of VA cancer treatment. 
Though these are important issues, future studies must extend 
beyond physical aspects of care and comprehensively assess 
patients’ cancer care, including psychosocial, spiritual, men-
tal, and palliative care needs.
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